Tackling Renal Disease in Lupus Patients

Research Brief

Tackling Renal Disease in Lupus Patients

Body

The autoimmune disease lupus can lead to serious kidney problems in up to 60 percent of patients, with 10-30 percent of patients ultimately developing end-stage renal disease (ESRD). The National Institute of Arthritis and Musculoskeletal and Skin Diseases has awarded Anna Broder, M.D., a five year, $880,000 grant to continue her research on the drug hydroxychloroquine, which  is used to treat lupus but is not widely used after lupus patients develop  ESRD. Dr. Broder will study whether hydroxychloroquine reduces mortality in lupus patients undergoing hemodialysis and kidney transplantation. This will involve analyzing data from a U.S. registry of ESRD patients and studying outcomes in lupus patient with ESRD who are being treated with hydroxychloroquine at Einstein and New York University School of Medicine. Dr. Broder is associate professor of medicine. (1K23AR068441-01A1)